About AVT
Browse Articles
Customer Services

Short communication

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

Rami Moucari, Michelle Martinot-Peignoux, Vincent Mackiewicz, Nathalie Boyer, Marie-Pierre Ripault, Corinne Castelnau, Laurence Leclere, Agnes Dauvergne, Dominique Valla, Michel Vidaud, Marie-Hélène Nicolas-Chanoine, Patrick Marcellin

Corresponding author name: Patrick Marcellin
Corresponding author e-mail: patrick.marcellin@bjn.aphp.fr

Citation: Antiviral Therapy 2009; 14:1183-1188
doi: 10.3851/IMP1458

Date accepted: 07 July 2009
Date published online: 10 December 2009


Background: The aim of this study was to assess the influence of hepatitis B virus (HBV) genotypes on serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative patients treated with pegylated interferon-α2a (PEG-IFN-α2a).

Methods: A total of 48 consecutive patients treated with PEG-IFN-α2a (180 μg/week) for 48 weeks were assessed. HBV genotype was determined. Serum HBV DNA and HBsAg were assessed at baseline, during treatment (weeks 12, 24 and 48) and during follow-up (weeks 72 and 96).

Results: The distribution of HBV genotype was A 27%, B 17%, C 12%, D 29% and E 14%. Mean ±sd pretreatment serum HBV DNA (6.9 ±1.5 log10 copies/ml) was not different between genotypes and decreased under treatment in all genotypes without significant difference. Mean ±sd pretreatment serum HBsAg (3.6 ±0.6 log10 IU/ml) was significantly different between genotypes (P<0.001), with high levels in genotypes A and C, intermediate levels in genotypes D and E, and low levels in genotype B (4.0 ±0.3, 4.1 ±0.7, 3.6 ±0.5, 3.6 ±0.4 and 2.7 ±0.6 log10 IU/ml, respectively). Serum HBsAg decreased under treatment in all genotypes with a significant difference. At the end of treatment, mean ±sd decrease was high in genotype A, intermediate in genotypes B and D, and low in genotypes C and E (1.3 ±1.6, 0.7 ±0.7, 0.6 ±0.9, 0.4 ±1.0 and 0.4 ±0.9 log10 IU/ml, respectively; P<0.001). During follow-up, serum HBsAg continued to decrease in genotypes A and D, whereas rebound was observed in genotypes B, C and E.

Conclusions: HBV genotype has a strong influence on serum HBsAg kinetics during PEG-IFN-α2a therapy in HBeAg-negative patients.


Copyright © Nucleus Global 2014. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.